AzurRx BioPharma

From Verify.Wiki
Jump to: navigation, search
AzurRx BioPharma
Type Public
Industry Pharmaceutical
Founded 2014
Headquarters Brooklyn, NY
Key people Thijs Spoor(President), Daniel Dupret(Chief Scientific Officer), George Harb(MD)[1]
Investors WallachBeth Capital and Network 1 Financial Securities[2][3]
Number of employees 12 [4]

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders[5]. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant ß-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is based in Brooklyn, New York.AzurRx BioPharma is developing a treatment for pancreatic insufficiency with the scientific backing of European biopharma researchers, it has earned Phase 1 clinical trial success for its lead candidate.[6]


  • July 31, 2014, AzurRx announces issuance of U.S. Patent for its MS1819 lipase compound.[7]
  • May 28, 2015, AzurRx announces addition of Ed Borkowski to the Board of Directors.[8]
  • January 11, 2016, AzurRx President Thijs Spoor made a presentation at the 8th Annual Biotech Showcase 2016 meeting in San Francisco.[9]
  • AzurRX and Protea Biosciences Group, Inc. and its wholly owned subsidiary Protea Biosciences, Inc. entered into a stock purchase and sale agreement with AzurRx BioPharma, Inc.[10][11]
  • October 12, 2016, AzurRx BioPharma Inc. announced that its initial public offering of 960,000 shares of common stock has been priced at $5.50 per share.[12][13]
  • October 12, 2016, AzurRX had to dip under its lowest range of $6 to $8 to just $5.50, raising $5 million through just under 1 million shares.[14]
  • October 19, 2016, AzurRx BioPharma Inc. to ring the Nasdaq stock market Closing Bell.[15]


Top 5 Recent Tweets

August 16, 2019WeekHeraldAzurRx BioPharma Inc $AZRX Given Average Rating of “Buy” by Brokerages
August 16, 2019ThisLincolnianAzurRx BioPharma Inc $AZRX Given Average Recommendation of “Buy” by Brokerages
August 15, 2019dakotafinancialAzurRx BioPharma’s $AZRX Buy Rating Reaffirmed at HC Wainwright
August 15, 2019incrediblebob12$AZRX P2 data due in next 2-6 weeks. Company completed an investor friendly offering 3 weeks ago. This is set to…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history